Valuation: BioNTech SE

Market Cap 21.61B 24.33B 20.21B 18.42B 34.67B 2,342B 35.15B 244B 94.64B 1,193B 91.34B 89.36B 3,832B P/E 2026 *
-15.1x
P/E 2027 * -15.8x
Enterprise Value 10.24B 11.53B 9.58B 8.73B 16.43B 1,110B 16.66B 116B 44.85B 565B 43.29B 42.35B 1,816B EV / Sales 2026 *
5.67x
EV / Sales 2027 * 6.39x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-14.84%+2.41% - - 24.33B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.66%-3.98%+27.05%+33.90% 42.91B
+0.87%+1.54%+355.43%+695.30% 44.13B
-1.94%-2.68%+1.74%+96.74% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.37%-7.53%-28.69%+329.48% 23.71B
Average -0.03%-0.64%+52.63%+158.73% 43.6B
Weighted average by Cap. +0.17%-0.40%+57.77%+150.53%

Financials

2026 *2027 *
Net sales 1.81B 2.03B 1.69B 1.54B 2.9B 196B 2.94B 20.44B 7.91B 99.75B 7.64B 7.47B 320B 1.81B 2.04B 1.69B 1.54B 2.91B 196B 2.95B 20.49B 7.93B 99.98B 7.66B 7.49B 321B
Net income -1.38B -1.55B -1.29B -1.17B -2.21B -149B -2.24B -15.57B -6.03B -76B -5.82B -5.69B -244B -1.31B -1.48B -1.23B -1.12B -2.1B -142B -2.13B -14.83B -5.74B -72.34B -5.54B -5.42B -232B
Net Debt -11.37B -12.8B -10.63B -9.69B -18.24B -1,232B -18.49B -129B -49.79B -628B -48.06B -47.01B -2,016B -10.03B -11.29B -9.38B -8.55B -16.09B -1,087B -16.31B -113B -43.92B -554B -42.39B -41.47B -1,778B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-